359 related articles for article (PubMed ID: 32676455)
1. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Weykamp F; König L; Seidensaal K; Forster T; Hoegen P; Akbaba S; Mende S; Welte SE; Deutsch TM; Schneeweiss A; Debus J; Hörner-Rieber J
Front Oncol; 2020; 10():987. PubMed ID: 32676455
[No Abstract] [Full Text] [Related]
2. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
Nagpal SK; Khabra K; Ross G; Kirby AM
Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):736-743. PubMed ID: 37684189
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
[TBL] [Abstract][Full Text] [Related]
4. Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease?
Aquilano M; Loi M; Visani L; Livi L; Nuyttens JJ
Acta Oncol; 2023 Mar; 62(3):298-304. PubMed ID: 36905644
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy.
Tsur E; Blumenfeld P; Rottenberg Y; Nechushtan H; Arnon J; Wald O; Izhar U; Pfeffer R; Krakow A; Wygoda M; Popovtzer A; Michaeli TF
Transl Lung Cancer Res; 2024 Mar; 13(3):465-474. PubMed ID: 38601442
[TBL] [Abstract][Full Text] [Related]
6. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiation therapy (SBRT) for patients with oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities profile in a monoinstitutional study.
Facondo G; Vullo G; Valeriani M; Ascolese AM; De Sanctis V; Osti MF
Cancer Treat Res Commun; 2021; 29():100481. PubMed ID: 34700142
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic radiotherapy in the management of oligometastatic and recurrent head and neck cancer: a single-center experience.
Mohamed AA; Goncalves M; Singh BP; Tometten M; Rashad A; Hölzle F; Hackenberg S; Eble M
Strahlenther Onkol; 2024 May; 200(5):400-408. PubMed ID: 38063900
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Body Radiotherapy for Extracranial Oligometastatic Disease from Head and Neck Primary Cancers: A Systematic Review and Meta-Analysis.
Mutsaers A; Akingbade A; Louie AV; Id Said B; Zhang L; Poon I; Smoragiewicz M; Eskander A; Karam I
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473213
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy for distant metastases to the head and neck.
Mutsaers A; Abugharib A; Poon I; Loblaw J; Bayley A; Zhang L; Chin L; Galapin M; Erler D; Sahgal A; Higgins K; Enepekides D; Eskander A; Karam I
Support Care Cancer; 2024 Mar; 32(4):230. PubMed ID: 38488881
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
12. Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer.
Xu B; Zhao X; Chen D; Zhao W; Wang X; Ding C; Yuan Z; Zhang H
BMC Cancer; 2023 Jan; 23(1):73. PubMed ID: 36681809
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: A single-institution experience.
Smile TD; Reddy CA; Qiao-Guan G; Winter WI; Stephans KL; Woody NM; Balagamwala EH; Amarnath SR; Magnelli A; AlHilli MM; Michener CM; Mahdi H; DeBernardo RL; Rose PG; Cherian SS
J Radiosurg SBRT; 2021; 7(3):189-197. PubMed ID: 33898082
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study.
Kroese TE; Jorritsma NKN; van Laarhoven HWM; Verhoeven RHA; Mook S; Haj Mohammad N; Ruurda JP; van Rossum PSN; van Hillegersberg R
Clin Transl Radiat Oncol; 2022 Nov; 37():109-115. PubMed ID: 36186924
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy in patients with adrenal gland metastases of oligometastatic and oliogoprogressive lung cancer.
Rzazade R; Pham NT; Turna M; Canoglu MD; Kucukmorkoc E; Berberoglu K; Caglar HB
J Radiosurg SBRT; 2022; 8(4):275-282. PubMed ID: 37416328
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
18. Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type.
Hu X; Li H; Liu H; Liu Z; Xia T; Zhang J; Wang Y
Transl Cancer Res; 2021 Jan; 10(1):184-194. PubMed ID: 35116250
[TBL] [Abstract][Full Text] [Related]
19. Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease.
Ramadan S; Quan K; Schnarr K; Juergens RA; Hotte SJ; Mukherjee SD; Kapoor A; Meyers BM; Swaminath A
Acta Oncol; 2022 Jun; 61(6):705-713. PubMed ID: 35435129
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
